NRC	FORM	374

U.S. NUCLEAR REGULATORY COMMISSION

PAGE __1__OF _3_ PAGES Amendment No. 23

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee

In accordance with letter dated

March 31, 2011,

- 1. Indiana University Health-White Memorial Hospital Inc.
- 720 South 6th Street Monticello, IN 47960

- 3. License number 13-20352-01 is amended in its entirety to read as follows:
- 4. Expiration date October 31, 2013
- 5. Docket No. 030-18288 Reference No.

- Byproduct, source, and/or special nuclear material
- 7. Chemical and/or physical form
- Maximum amount that licensee may possess at any one time under this license

- A. Any byproduct material permitted by 10 CFR 35.100
- A. Any

A. As needed

- B. Any byproduct material permitted by 10 CFR 35.200
- B. Any

B. As needed

- 9. Authorized use:
 - A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
 - B. Any imaging and localization study permitted by 10 CFR 35.200.

CONDITIONS

- 10. Location of Use: 720 South Sixth Street, Monticello, Indiana.
- 11. Radiation Safety Officer: Patrick J. Byrne, DABR, CHP, DABSNM
- 12. Licensed material is only authorized for use by, or under the supervision of:
 - A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
 - B. The following individuals are authorized users for medical use as indicated:

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION	PAGE	2	of	3	PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number 13-20352-01 Docket or Reference Number 030-18288	-				
		Amendment No. 23				

Authorized Users	Material and Use
William J. Miller, M.D.	10 CFR 35.100 and 35.200
Rodney A. Dunseath, D.O.	10 CFR 35.100 and 35.200
Phyllis Martin-Simmerman, M.D.	10 CFR 35.100 and 35.200
Jeffry S. Cahoon, M.D.	10 CFR 35.100 and 35.200
Mark C. Arvin, M.D.	10 CFR 35.100 and 35.200
Douglas M. Dunco, M.D.	10 CFR 35.100 and 35.200
Paul E. Timperman, M.D.	10 CFR 35.100 and 35.200
Charles M. Orr, M.D.	
Michael L. Smith, M.D.	10 CFR 35.100 and 35.200.
Charles P. Taliercio, M.D.	10 CFR 35.100 and 35.200.
Fred Spottsville, M.D.	10 CFR 35.100 and 35.200.
•	10 CFR 35.100 and 35.200.
Michael W. Ball, M.D.	10 CFR 35.100 and 35.200.
Gregory B. Elsner, M.D.	10 CFR 35.100 and 35.200.
Daniel M. Gelfman, M.D.	10 CFR 35.100 and 35.200.
Kamthorn S. Lee, M.D.	10 CFR 35.200.
Roderick Sawyer, M.D.	10 CFR 35.100 and 35.200.
David R. Schmidt, M.D.	10 CFR 35.100 and 35.200.
Martin See, M.D.	10 CFR 35.100 and 35.200.
Jospeh E. Steinmetz, M.D.	10 CFR 35.100 and 35.200.
Morton Tavel, M.D.	10 CFR 35.100 and 35.200.
Mary M. Walsh, M.D.	10 CFR 35.100 and 35.200.
Sam Hansen, M.D.	10 CFR 35.100 and 35.200,
James M. Scheffler, M.D.	10 CFR 35.200.
Peter Nechay, M.D.	10 CFR 35.100 and 35.200.
Thomas P. Schleeter, M.D.	10 CFR 35.100 and 35.200
Ali Nawab Rizvi, M.D.	10 CFR 35.200.
Michael Elliott, M.D.	10 CFR 35.200.

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION	PAGE	3	of	3	PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number 13-20352-01					
	Docket or Reference Number 030-18288					
	Amendment No. 23					

Authorized Users

Material and Use

Anthony J. Cossell, M.D.

10 CFR 35.200

Christopher J. Hollon, M.D.

10 CFR 35.100 and 35.200.

George K. Brodell, M.D.

10 CFR 35.100 and 35.200.

Steven Hossler, M.D.

10 CFR 35.100 and 35.200.

- 13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
- 14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
- 15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
 - A. Application dated October 1, 2003; and
 - B. Letters dated June 19, 2008, November 5, 2008, October 7, 2009 and March 31, 2011.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date JUN 1 7 2011

Toye L. Simmons

Materials Licensing Branch

Region III